FDA Greenlights SofdraTM for Hyperhidrosis Treatment, Botanix Secures $70M
FDA approves Botanix's SofdraTM for axillary hyperhidrosis; $70M raised, launch in Q3 2024.
For the purpose of treating primary axillary hyperhidrosis, Botanix Pharmaceuticals Limited's innovative dermatological treatment, SofdraTM, has been approved by the FDA. Through a successful placement, the business has secured $70 million to finance the launch, which is scheduled to start with a patient experience program in Q3 2024 and move into a more comprehensive digital release in Q4. With no debt and a healthy financial position, Botanix is well-positioned to take on the roughly 10 million Americans who suffer from this illness.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion